ATE182141T1 - Bifunktionale kupplungsverbindungen, konjugate und verfahren zu ihrer herstellung - Google Patents

Bifunktionale kupplungsverbindungen, konjugate und verfahren zu ihrer herstellung

Info

Publication number
ATE182141T1
ATE182141T1 AT91107737T AT91107737T ATE182141T1 AT E182141 T1 ATE182141 T1 AT E182141T1 AT 91107737 T AT91107737 T AT 91107737T AT 91107737 T AT91107737 T AT 91107737T AT E182141 T1 ATE182141 T1 AT E182141T1
Authority
AT
Austria
Prior art keywords
conjugates
methods
novel
bifunctional compounds
production
Prior art date
Application number
AT91107737T
Other languages
English (en)
Inventor
Takushi Kaneko
David Willner
Ivo Monkovic
Robert S Greenfield
Gary R Braslawsky
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE182141T1 publication Critical patent/ATE182141T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Static Random-Access Memory (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Measurement Of Radiation (AREA)
AT91107737T 1990-05-14 1991-05-13 Bifunktionale kupplungsverbindungen, konjugate und verfahren zu ihrer herstellung ATE182141T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07522996 US5137877B1 (en) 1990-05-14 1990-05-14 Bifunctional linking compounds conjugates and methods for their production

Publications (1)

Publication Number Publication Date
ATE182141T1 true ATE182141T1 (de) 1999-07-15

Family

ID=24083237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91107737T ATE182141T1 (de) 1990-05-14 1991-05-13 Bifunktionale kupplungsverbindungen, konjugate und verfahren zu ihrer herstellung

Country Status (14)

Country Link
US (2) US5137877B1 (de)
EP (1) EP0457250B1 (de)
JP (2) JP3010319B2 (de)
AT (1) ATE182141T1 (de)
AU (1) AU646850B2 (de)
CA (1) CA2042503C (de)
DE (1) DE69131435T2 (de)
DK (1) DK0457250T3 (de)
ES (1) ES2134761T3 (de)
FI (1) FI100718B (de)
GR (1) GR3031402T3 (de)
IE (1) IE911635A1 (de)
PT (1) PT97639B (de)
ZA (1) ZA913591B (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
WO1993020834A1 (en) * 1992-04-10 1993-10-28 Brigham And Women's Hospital Methods and compositions for oral delivery of therapeutic agents
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
WO1995006255A1 (en) * 1993-08-27 1995-03-02 Abbott Laboratories Hydrazine derivatized cells
US5858327A (en) * 1993-09-03 1999-01-12 Resolutions Pharmaceuticals, Inc. Hydrazino-type N2 S2 radionuclide chelating compounds
US5502246A (en) * 1994-03-22 1996-03-26 Eli Lilly And Company Solid-phase synthesis utilizing photochemical carbon-sulfur bond cleavage of thioethers
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5856571A (en) * 1995-06-07 1999-01-05 Cellpro, Incorporated Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto
AU708475B2 (en) * 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
EP0871490B1 (de) * 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Verzweigte hydrazongruppen enthaltende kuppler
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1998019705A1 (en) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
US6127333A (en) * 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6299860B1 (en) * 1998-10-15 2001-10-09 Fluoro Probe, Inc. Method for viewing diseased tissue located within a body cavity
US6652836B2 (en) 1998-10-15 2003-11-25 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
US6222093B1 (en) * 1998-12-28 2001-04-24 Rosetta Inpharmatics, Inc. Methods for determining therapeutic index from gene expression profiles
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US7192729B2 (en) 1999-07-06 2007-03-20 General Atomics Methods for assaying homocysteine
WO2001062968A2 (en) * 2000-02-25 2001-08-30 General Atomics Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods
AU2001250898A1 (en) * 2000-03-17 2001-10-03 The Salk Institute For Biological Studies Compositions associated with complex formation
US6610504B1 (en) 2000-04-10 2003-08-26 General Atomics Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase
GB0012718D0 (en) * 2000-05-24 2000-07-19 Angeletti P Ist Richerche Bio Conjugates of aminodrugs
AU2001283740A1 (en) * 2000-08-17 2002-02-25 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
AU2001285020A1 (en) * 2000-08-17 2002-02-25 Synapse Technologies, Inc. P97-active agent conjugates and their methods of use
US7445802B2 (en) * 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
US7087600B2 (en) 2001-05-31 2006-08-08 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
US20030232760A1 (en) * 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
RU2196604C1 (ru) * 2001-12-21 2003-01-20 Северин Евгений Сергеевич Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
US7282590B2 (en) * 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
US7384760B2 (en) * 2004-04-30 2008-06-10 General Atomics Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase
US7517903B2 (en) * 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
JP5149620B2 (ja) * 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
MX2007009878A (es) * 2005-02-18 2007-10-03 Medarex Inc Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep).
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP3539572A1 (de) * 2005-08-24 2019-09-18 ImmunoGen, Inc. Verfahren zur herstellung von maytansinoid-antikörper-konjugaten
AU2006294554B2 (en) * 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
CN101365679B (zh) 2005-10-26 2012-11-14 梅达莱克斯公司 制备cc-1065类似物的方法和化合物
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
KR20090122439A (ko) * 2007-02-21 2009-11-30 메다렉스, 인코포레이티드 단일 아미노산을 갖는 화학적 링커 및 이의 접합체
EP3486653A1 (de) 2007-05-24 2019-05-22 The United States Government as represented by The Department of Veterans Affairs Nutzung des ent2 transporters für die beahndlung von skeletaler muskelerkrankung
WO2009039207A1 (en) * 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
EP2281006B1 (de) * 2008-04-30 2017-08-02 Immunogen, Inc. Vernetzer und ihre verwendung
AU2015202204A1 (en) * 2008-04-30 2015-05-14 Immunogen, Inc. Cross-linkers and their uses
KR101810110B1 (ko) * 2008-05-27 2017-12-18 젠자임 코포레이션 알파-멜라노사이트 자극 호르몬의 펩티드 유사체
EP2376534A4 (de) 2008-12-05 2012-05-30 Abraxis Bioscience Llc SPARC-BINDENDE ScFc
US9155801B2 (en) 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
EP2437790B1 (de) 2009-06-03 2019-02-20 Immunogen, Inc. Konjugationsverfahren
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
TR201902180T4 (tr) 2011-03-29 2019-03-21 Immunogen Inc Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
EP2592103A1 (de) 2011-11-08 2013-05-15 Adriacell S.p.A. Polymeraldehydderivate
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
SG11201605260VA (en) 2013-12-27 2016-07-28 Zymeworks Inc Var2csa-drug conjugates
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
EP3194421B1 (de) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxische und antimitotische verbindungen und verfahren zur verwendung davon
JP6921743B2 (ja) 2014-11-05 2021-08-18 ナンヤン テクノロジカル ユニヴァーシティー 安定化かつ自律性抗体ｖｈドメイン
EP3319936B1 (de) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Brückenlinker zur konjugation von zellbindenden molekülen
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3355930A4 (de) * 2015-10-01 2019-03-06 Warp Drive Bio, Inc. Verfahren und reagenzien zur analyse von protein-protein-schnittstellen
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
WO2019152806A1 (en) 2018-02-01 2019-08-08 Yale University Compositions and methods for enhancing nuclear translocation
WO2022013613A2 (en) 2020-07-17 2022-01-20 Onena Medicines S.L. Antibodies against lefty proteins
CN113262311B (zh) * 2021-04-29 2022-08-05 武汉纳乐吉生命科技有限公司 肿瘤特异性刺激响应的羟烷基淀粉-阿霉素偶联物、其制备和应用
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
WO2023056450A1 (en) 2021-09-30 2023-04-06 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN120129696A (zh) 2022-09-01 2025-06-10 乔治亚大学研究基金公司 用于指导载脂蛋白l1诱导哺乳动物细胞死亡的组合物和方法
US20260103629A1 (en) 2022-09-20 2026-04-16 Yale University Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof
CN120787163A (zh) 2022-12-27 2025-10-14 耶鲁大学 抗体药物缀合物
CN121693350A (zh) * 2023-01-20 2026-03-17 艾德森特克斯治疗股份有限公司 药物偶联物及其制备与使用方法
EP4655007A1 (de) 2023-01-23 2025-12-03 Yale University Antikörper-oligonukleotid-konjugate
EP4683674A1 (de) 2023-03-23 2026-01-28 Yale University Zusammensetzungen und verfahren zur abgabe von antikörper-oligonukleotid-konjugaten für exon-skipping

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470054A1 (de) * 1963-11-09 1969-05-29 Merck Ag E Schwefelhaltige Pyridin-Derivate und Verfahren zu deren Herstellung
US4130562A (en) * 1975-01-10 1978-12-19 Givaudan Corporation Odorant or flavoring thiazolyl disulphides
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
US4112217A (en) * 1977-09-02 1978-09-05 Sri International Bis-hydrazones of daunomycin and adriamycin
US4250303A (en) * 1977-10-17 1981-02-10 Sri International N-Benzyl anthracyclines
US4258193A (en) * 1978-07-13 1981-03-24 Toyo Jozo Kabushiki Kaisha Disulfide derivatives having S--S exchange reactivity
US4303785A (en) * 1978-08-05 1981-12-01 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Antitumor anthracycline antibiotics
US4202967A (en) * 1978-10-02 1980-05-13 Sri International N,N-pentamethylene derivatives of daunomycin and adriamycin
US4282031A (en) * 1979-01-03 1981-08-04 Gulf Oil Corporation Substituted thiosemicarbazides, their manufacture and use as plant growth regulants
US4252962A (en) * 1980-03-24 1981-02-24 Olin Corporation Process for producing 2-amino or selected 2-(substituted)amino-5-mercapto-1,3,4-thiadiazole compounds
US4301277A (en) * 1980-10-20 1981-11-17 Sri International 3-Deamino-3-(4-morpholinyl) derivatives of daunorubicin and doxorubicin
US4314054A (en) * 1981-03-23 1982-02-02 Sri International 3'-Deamino-3'-(4-methoxy-1-piperidinyl) derivatives of daunorubicin and doxorubicin
SE8102193L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och dess anvendning
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
ES522315A0 (es) * 1982-05-12 1984-08-16 Harvard College Un procedimiento para obtener una proteina hibrida.
GB2122612B (en) * 1982-06-16 1985-09-25 May & Baker Ltd Cystamine derivatives
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
US4590001A (en) * 1983-03-28 1986-05-20 Stjernholm Rune L Platinum bound to transferrin for use in the treatment of breast tumors
SE8302758L (sv) * 1983-05-17 1984-11-18 Pharmacia Ab Sett for uppspjelkning av disulfidbindningar och derigenom erhallen forening
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
JPS6157579A (ja) * 1984-08-29 1986-03-24 Toyama Chem Co Ltd ３−アミノピロリジンまたはその塩の製造法
US4591637A (en) * 1985-01-17 1986-05-27 Sri International Open chain-morpholino adriamycins
JPS61274658A (ja) * 1985-05-29 1986-12-04 Morii Shokuhin Kk 半生状はるさめの製造方法
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
IN165717B (de) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US4970303A (en) * 1988-02-03 1990-11-13 Xoma Corporation Linking agents and methods
FI102355B1 (fi) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent

Also Published As

Publication number Publication date
FI912285L (fi) 1991-11-15
DE69131435D1 (de) 1999-08-19
IE911635A1 (en) 1991-11-20
CA2042503C (en) 2002-07-23
JPH04352765A (ja) 1992-12-07
FI100718B (fi) 1998-02-13
US5349066A (en) 1994-09-20
DK0457250T3 (da) 1999-11-29
CA2042503A1 (en) 1991-11-15
PT97639A (pt) 1992-02-28
EP0457250B1 (de) 1999-07-14
ZA913591B (en) 1992-02-26
EP0457250A3 (en) 1992-07-01
JP3010319B2 (ja) 2000-02-21
US5137877B1 (en) 1996-01-30
EP0457250A2 (de) 1991-11-21
AU7403891A (en) 1991-11-14
US5137877A (en) 1992-08-11
AU646850B2 (en) 1994-03-10
FI912285A0 (fi) 1991-05-10
GR3031402T3 (en) 2000-01-31
JP2000026404A (ja) 2000-01-25
DE69131435T2 (de) 2000-03-23
PT97639B (pt) 1998-08-31
ES2134761T3 (es) 1999-10-16
JP3234980B2 (ja) 2001-12-04

Similar Documents

Publication Publication Date Title
US5137877B1 (en) Bifunctional linking compounds conjugates and methods for their production
EP1372735B1 (de) Hydroxyalkylstärke-wirkstoff-konjugate
Alam et al. Boron neutron capture therapy: linkage of a boronated macromolecule to monoclonal antibodies directed against tumor-associated antigens
AU618995B2 (en) Pharmaceutical formulations for parenteral use
US4263279A (en) Pharmaceutically active compositions containing adriamycin and daunomycin
JPH03502098A (ja) 酸性化された細胞内小胞内で開裂可能な蛋白質架橋試薬
JP4794735B2 (ja) ビタミンｂ１２誘導体及びそれらの製造方法
JPH10502334A (ja) 受容体調節剤およびこれに関連した方法
KR900002803A (ko) 세포독성 약물 결합체
JPS6112630A (ja) 免疫毒素およびその製造法
AU7331094A (en) A3 adenosine receptor agonists
ATE150321T1 (de) Anthracyclin-konjugate mit einem neuen linker und verfahren zu dessen herstellung
HUT73227A (en) Colon- or ileum-specific steroid derivatives, containing sugar, their production and pharmaceutical compositions
KR0185967B1 (ko) 치료용 약물의 부위 특이적 생체내 활성작용
IL64722A0 (en) Immunoglobin conjugates,their preparation and pharmaceutical compositions containing them
JPH03505576A (ja) 有機化合物に関する改良
KR0130906B1 (ko) 면역글로불린 결합체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
CA1224718A (en) Anti-cancer drugs comprising platinum complexes
DE69310052D1 (de) Kardioaktive 17B-(3-Furyl) und 17B-(4-Pyridazinyl)-5beta, 14beta-Androstan Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Präparate davon
Wilchek Affinity therapy and polymer bound drugs
EP0476408A1 (de) Chemische Konjugation von Morpholino-Anthracyclinen mit Antikörpern
CA2086679A1 (en) Receptor directed-toxin conjugates
DE68902212T2 (de) Immunotoxine zur behandlung bzw. prophylaxe von autoimmunkrankheiten.
ES8203334A1 (es) Procedimiento para la obtencion de dehidropeptidos
EP0341661A3 (de) Alpha-Aminoborsäure-Derivate enthaltende Peptid-Mittel Zusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee